SUPN FY 2017 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$302M+40.6% YoY

Gross Profit

$287M95.0% margin

Operating Income

$100M32.9% margin

Net Income

$57M19.0% margin

EPS (Diluted)

$1.08

Cash Flow

Operating Cash Flow

$115M

Free Cash Flow

$113M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$424M

Total Liabilities

$157M

Stockholders' Equity

$267M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$302M	$215M	+40.6%
Gross Profit	$287M	$203M	+41.4%
Operating Income	$100M	$54M	+83.6%
Net Income	$57M	$91M	-37.2%